|
|
Volumn 333, Issue 6039, 2011, Pages 143-144
|
|
Once on 'fast track,' avastin now derailed
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
VASCULOTROPIN;
ANGIOGENESIS INHIBITOR;
MONOCLONAL ANTIBODY;
ANTIBODY;
CANCER;
CHEMOTHERAPY;
DRUG PRESCRIBING;
HEALTH RISK;
HEALTH SERVICES;
PERFORMANCE ASSESSMENT;
PUBLIC HEALTH;
RESEARCH WORK;
BREAST CANCER;
CANCER SURVIVOR;
DRUG APPROVAL;
DRUG COST;
DRUG POTENCY;
FOLLOW UP;
FOOD AND DRUG ADMINISTRATION;
HEALTH HAZARD;
HUMAN;
METASTASIS;
PERFORMANCE;
PRIORITY JOURNAL;
QUALITY OF LIFE;
SHORT SURVEY;
BREAST TUMOR;
ECONOMICS;
FEMALE;
MORTALITY;
NOTE;
SURVIVAL RATE;
UNITED STATES;
UNITED STATES;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL;
BREAST NEOPLASMS;
DRUG APPROVAL;
DRUG COSTS;
FEMALE;
HUMANS;
SURVIVAL RATE;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 79960108792
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.333.6039.143 Document Type: Short Survey |
|
Times cited : (15)
|
|
References (0)
|
